HSK47388

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

TicsPsoriasisUlcerative Colitis

108 competitors in Tics

#DrugCompanyPhaseTrials

1

Sodium Valproate

AstraZeneca

Phase 3

12

Rifadin

Sanofi

Phase 1

263

Priftin

Sanofi

Phase 2

14

Nydrazid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

45

Sporanox

SSebela Pharmaceuticals Development LLC

Phase 1

546

Duvyzat

Italfarmaco

Phase 2

27

Dilaudid

RRhodes Pharmaceuticals, L.P.

Phase 2

18

Taltz

Eli Lilly

Phase 1

19

Aciphex

Akero Therapeutics

Phase 1

910

DTIC-Dome

Bayer

Phase 1

1Show 36 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Ulcerative Colitis1 trial

A Study for HSK47388 in Participants With Ulcerative Colitis

Recruiting·Haisco Pharmaceutical Group Co., Ltd.·Phase 2·NCT07335055·150 enrolled

Tics1 trial

This Study is to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of HSK47388 in Healthy Volunteers

Not yet recruiting·Haisco Pharmaceutical Group Co., Ltd.·Phase 1·NCT06926218·40 enrolled

Psoriasis1 trial

A Phase 2 Study of HSK47388 Tablets to Evaluate the Efficacy and Safety in Patients With Moderate-to-Severe Plaque Psoriasis

Not yet recruiting·Haisco Pharmaceutical Group Co., Ltd.·Phase 2·NCT07158268·220 enrolled

Details

Drug Info

Related News